{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:00:09Z","timestamp":1793829609061,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and triplet therapy (which includes chemotherapy in addition to doublet therapy). However, differences in therapeutic efficacy between the two groups remain unclear. The aim of the study was to perform a comparative analysis between the two groups and to identify predictors of treatment response. We retrospectively recruited 500 patients with mHSPC treated with doublet or triplet therapy from our hospital and affiliated hospitals between 2013 and 2025. The cohort of patients with mHSPC treated with doublet therapy received ABI, ENZ, or APA in combination with a luteinizing hormone-releasing hormone analog, such as androgen deprivation therapy (ADT). The cohort of those treated with triplet therapy received darolutamide plus ADT and docetaxel. Cox proportional hazards regression analysis was performed to identify prognostic factors of overall survival in patients with mHSPC. Propensity score matching was used to adjust the clinical background of patients. The outcome (prostate-specific antigen-progression-free survival, second progression-free survival, and overall survival (OS)) of triplet therapy was significantly better than that of doublet therapy in matched high-risk patients with mHSPC. Univariate and multivariate analyses of OS in matched patients with high-risk mHSPC treated with triplet or doublet therapy suggested that treatment choice (triplet or doublet), pretreatment LDH levels, and presence of Gleason pattern 5 influenced OS in patients with high-risk mHSPC. Subgroup analysis suggested that LDH levels and the presence of Gleason pattern 5 may be predictive factors of the treatment of patients with mHSPC. Our results showed that triplet therapy achieved a better outcome than doublet therapy in patients with mHSPC.<\/jats:p>","DOI":"10.1038\/s41598-026-44627-w","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:27:08Z","timestamp":1773696428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Keita","family":"Hayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Gabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Murashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Okumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"44627_CR1","unstructured":"NCCN Guidelines Version 2. (2026)."},{"issue":"4","key":"44627_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352\u201360 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"44627_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121\u201331 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"44627_CR4","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi, K. N. et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39(20), 2294\u2013303 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"44627_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz, I. B. et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: A living systematic review and network meta-analysis. JAMA Oncol. 9(5), 635\u201345 (2023).","journal-title":"JAMA Oncol."},{"issue":"4","key":"44627_CR6","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/aja20242","volume":"26","author":"SS Wang","year":"2024","unstructured":"Wang, S. S. et al. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer. Asian J. Androl. 26(4), 402\u20138 (2024).","journal-title":"Asian J. Androl."},{"issue":"2","key":"44627_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.euf.2024.11.004","volume":"11","author":"B Hoeh","year":"2025","unstructured":"Hoeh, B. et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: An updated network meta-analysis including ARANOTE data. Eur. Urol. Focus 11(2), 386\u201390 (2025).","journal-title":"Eur. Urol. Focus"},{"issue":"5","key":"44627_CR8","doi-asserted-by":"publisher","first-page":"252 e19","DOI":"10.1016\/j.urolonc.2023.03.013","volume":"41","author":"B Lowentritt","year":"2023","unstructured":"Lowentritt, B. et al. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study. Urol. Oncol. 41(5), 252 e19-e27 (2023).","journal-title":"Urol. Oncol."},{"issue":"1","key":"44627_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/pros.24802","volume":"85","author":"S Narita","year":"2025","unstructured":"Narita, S. et al. Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. Prostate 85(1), 73\u201381 (2025).","journal-title":"Prostate"},{"issue":"12","key":"44627_CR10","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1007\/s00345-022-04200-2","volume":"40","author":"T Ueda","year":"2022","unstructured":"Ueda, T. et al. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients. World J. Urol. 40 (12), 2939\u20132946 (2022).","journal-title":"World J. Urol."},{"issue":"6","key":"44627_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/pros.24855","volume":"85","author":"T Ueda","year":"2025","unstructured":"Ueda, T. et al. Screening for predictive factors of efficacy of second-generation androgen receptor axis-targeted agents in patients with high-risk metastatic hormone-sensitive prostate cancer. Prostate 85(6), 524\u201330 (2025).","journal-title":"Prostate"},{"issue":"12","key":"44627_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl. J. Med. 386 (12), 1132\u20131142 (2022).","journal-title":"N Engl. J. Med."},{"issue":"7","key":"44627_CR13","doi-asserted-by":"publisher","first-page":"e250023","DOI":"10.57264\/cer-2025-0023","volume":"14","author":"B Lowentritt","year":"2025","unstructured":"Lowentritt, B. et al. Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: A head-to-head analysis of real-world patients in the USA. J. Comp. Eff. Res. 14(7), e250023 (2025).","journal-title":"J. Comp. Eff. Res."},{"issue":"2","key":"44627_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.eururo.2021.11.020","volume":"81","author":"F Saad","year":"2022","unstructured":"Saad, F. et al. Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN. Eur. Urol. 81(2), 184\u201392 (2022).","journal-title":"Eur. Urol."},{"key":"44627_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04465-7","author":"K Usui","year":"2025","unstructured":"Usui, K. et al. Short-term outcomes of triplet therapy in metastatic hormone-sensitive prostate cancer in older adults: A retrospective, single-center real-world cohort study. Int. Urol. Nephrol. https:\/\/doi.org\/10.1007\/s11255-025-04465-7 (2025).","journal-title":"Int. Urol. Nephrol."},{"key":"44627_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.955925","volume":"13","author":"T Jian","year":"2022","unstructured":"Jian, T. et al. Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Front. Pharmacol. 13, 955925 (2022).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"44627_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0115","volume":"2","author":"M Shiota","year":"2019","unstructured":"Shiota, M. et al. Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone. JAMA Netw. Open 2(2), e190115 (2019).","journal-title":"JAMA Netw. Open"},{"issue":"19","key":"44627_CR18","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1002\/cam4.3108","volume":"9","author":"F Li","year":"2020","unstructured":"Li, F. et al. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis. Cancer Med. 9 (19), 7341\u20137351 (2020).","journal-title":"Cancer Med."},{"issue":"26","key":"44627_CR19","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1200\/JCO.2006.05.9501","volume":"24","author":"MI Koukourakis","year":"2006","unstructured":"Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Gatter, K. C. & Harris, A. L. Tumour Angiogenesis Research G. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway\u2013a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol. 24 (26), 4301\u20134308 (2006).","journal-title":"J. Clin. Oncol."},{"key":"44627_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112666","author":"HF Cabanos","year":"2021","unstructured":"Cabanos, H. F. & Hata, A. N. Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13112666 (2021).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"44627_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2021.09.030","volume":"81","author":"RP Graf","year":"2022","unstructured":"Graf, R. P. et al. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. Eur. Urol. 81 (1), 37\u201347 (2022).","journal-title":"Eur. Urol."},{"key":"44627_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00081","author":"PI Velho","year":"2019","unstructured":"Velho, P. I. et al. Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.19.00081 (2019).","journal-title":"JCO Precis. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44627-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44627-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:14:03Z","timestamp":1781640843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44627-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44627"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44627-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8360739\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Boards of Kyoto Prefectural University of Medicine (ERB-C-1071-2). The study was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for written informed consent was waived owing to the retrospective nature of this study. Patients were provided with opt-out information on the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"13707"}}